KCNH2 and familial long QT syndrome: Since the discovery of the first hERG activator in 2005, it has now emerged that type 1 hERG activators, as opposed to other types of hERG agonist (particularly type 2 with their strong modulation of inactivation gating and related increased pro‐arrhythmic risk), may constitute good candidates for the pharmacological management of congenital and drug‐induced LQTS.